Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 8/20 | 0.48 |
| ▸ | CA9 | Q16790 | 8/20 | 0.48 |
| ▸ | CA1 | P00915 | 7/20 | 0.48 |
| ▸ | CA6 | P23280 | 4/20 | 0.48 |
| ▸ | CA7 | P43166 | 4/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA4 | P22748 | 3/20 | 0.48 |
| ▸ | CA5A | P35218 | 2/20 | 0.48 |
| ▸ | CA3 | P07451 | 2/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2639853 | 0.87 | MAOB (0.51) | MAOBDRD2DRD3CA12CA9 | |
| SCHEMBL4308719 | 0.85 | KDM4E (0.55) | MAOBDRD2DRD3CA12CA9 | |
| SCHEMBL4324590 | 0.78 | IKBKB (0.44) | — | |
| SCHEMBL2641077 | 0.77 | MAOB (0.53) | MAOBDRD2DRD3CA12CA9 | |
| SCHEMBL12304245 | 0.74 | CA12 (0.81) | MAOBCA12CA9CA1CA6 | |
| SCHEMBL4315261 | 0.73 | CHRNB2 (0.46) | CYP1A2 | |
| SCHEMBL4317120 | 0.71 | MCL1 (0.48) | CA12CA9CA1CA7CYP1A2 | |
| SCHEMBL15702993 | 0.69 | DRD2 (0.67) | MAOBDRD2DRD3 | |
| SCHEMBL4313514 | 0.69 | HTR2C (0.48) | DRD3NPC1 | |
| SCHEMBL24045405 | 0.69 | CA12 (0.82) | MAOBCA12CA9CA1CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534794-B2 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM AB (SE) | 2009-05-19 | — | — | US | claimed |
| US-7534794-B2 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM AB (SE) | 2009-05-19 | — | — | US | disclosed |
| US-7071180-B2 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM AB (SE) | 2006-07-04 | — | — | US | disclosed |
| US-20040242554-A1 | CERTAIN ARYLALIPHATIC AND HETEROARYL-ALIPHATIC PIPERAZINYL PYRAZINES AND THEIR USE IN THE TREATMENT OF SEROTONIN-RELATED DISEASES | BIOVITRUM, AB, A STOCKHOLM, SWEDEN CORPORATION | 2004-12-02 | — | — | US | disclosed |
| US-20030092694-A1 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM, AB, A STOCKHOLM, SWEDEN CORPORATION | 2003-05-15 | — | — | US | disclosed |
| US-6465467-B1 | DISEASES RELATED TO THE 5-HT2C RECEPTOR, ESPECIALLY EATING, MEMORY, MOOD, URINARY AND ANXIETY DISORDERS, SCHIZOPHRENIA, PAIN, SEXUAL DYSFUNCTIONS | BIOVITRUM AB (SE) | 2002-10-15 | — | — | US | disclosed |
| EP-1178973-A2 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | Pharmacia AB (SE) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000076984-A2 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB (SE) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092694-A1 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | HTR2C, HTR3C, HTR2A | MAOB 107/4885DRD2 52/4885DRD3 116/4885 |
| US-20040242554-A1 | CERTAIN ARYLALIPHATIC AND HETEROARYL-ALIPHATIC PIPERAZINYL PYRAZINES AND THEIR USE IN THE TREATMENT OF SEROTONIN-RELATED DISEASES | HTR2C, HTR3C, HTR2A | MAOB 100/4885DRD2 50/4885DRD3 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.